PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Ceralasertib

Drugs in development · updated 30 October 2026

Ceralasertib: clinical trials and development status

Other names and codes: AZD6738

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Ceralasertib is in 25 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

25Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Ceralasertib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII5NCT06732401
Lung neoplasmIII3NCT06732401
Breast neoplasmII3NCT04090567
Endometrial neoplasmII3NCT03682289
Triple-negative breast neoplasmII3NCT03330847
CarcinosarcomaII2NCT04065269
MetastasisII2NCT03682289
NeoplasmII2NCT05941897
Ovarian neoplasmII2NCT03579316
Bronchial neoplasmII1NCT05941897
Carcinoma, BronchogenicII1NCT05941897
Carcinoma, EndometrioidII1NCT04065269
CholangiocarcinomaII1NCT03878095
Fallopian tube neoplasmII1NCT03579316
Lung diseaseII1NCT05941897
Lung small cell carcinomaII1NCT06769126
MelanomaII1NCT05061134
OsteosarcomaII1NCT04417062
Pancreatic neoplasmII1NCT03682289
Prostatic NeoplasmsII1NCT03787680
Renal cell carcinomaII1NCT03682289
Respiratory diseaseII1NCT05941897
Respiratory tract neoplasmII1NCT05941897
Thoracic NeoplasmsII1NCT05941897
Transitional cell carcinomaII1NCT03682289
Uterine cervix neoplasmII1NCT04065269
Chronic lymphocytic leukemiaI1NCT03328273
Colonic neoplasmI1NCT04704661
Colorectal neoplasmI1NCT04704661
LeukemiaI1NCT03770429

Everything on Ceralasertib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch